fasudil has been researched along with chronic COVID syndrome in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sykes, RA | 1 |
| Neves, KB | 1 |
| Alves-Lopes, R | 1 |
| Caputo, I | 1 |
| Fallon, K | 1 |
| Jamieson, NB | 1 |
| Kamdar, A | 1 |
| Legrini, A | 1 |
| Leslie, H | 1 |
| McIntosh, A | 1 |
| McConnachie, A | 1 |
| Morrow, A | 1 |
| McFarlane, RW | 1 |
| Mangion, K | 1 |
| McAbney, J | 1 |
| Montezano, AC | 1 |
| Touyz, RM | 1 |
| Wood, C | 1 |
| Berry, C | 1 |
1 other study available for fasudil and chronic COVID syndrome
| Article | Year |
|---|---|
Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Cardiovascular Diseases; COVID-1 | 2023 |